News & Updates
Filter by Specialty:
Artificial pancreas yields good results in type 2 diabetes patients
A fully closed-loop insulin delivery system, also known as artificial pancreas, helps improve the management of type 2 diabetes in adults, increasing the time spent in target glucose range by 8 hours per day without promoting hypoglycaemic events as compared with standard insulin therapy, as reported in a study.
Artificial pancreas yields good results in type 2 diabetes patients
17 Jan 2023Higher LDL triglycerides up atherosclerotic CVD risk
Elevated low-density lipoprotein (LDL) triglycerides appear to increase the risk of atherosclerotic cardiovascular disease (ASCVD) and of each ASCVD component, according to a study.
Higher LDL triglycerides up atherosclerotic CVD risk
16 Jan 2023Diet with hyperinsulinaemic potential ups risk of breast cancer
Women with a dietary pattern contributing to hyperinsulinaemia and insulin resistance appear to be at increased risk of breast cancer, particularly estrogen-receptor (ER)-negative and human epidermal growth factor receptor 2 (HER2)-enriched tumours, reveals a study.
Diet with hyperinsulinaemic potential ups risk of breast cancer
15 Jan 2023Regular coffee intake may lower T2D risk in women with gestational diabetes
Women with a history of gestational diabetes mellitus (GDM) may benefit from habitual consumption of caffeinated coffee to prevent progression to type 2 diabetes (T2D) and have a more favourable metabolic profile, suggests a study.
Regular coffee intake may lower T2D risk in women with gestational diabetes
13 Jan 2023Lower plasma ACE2 levels may partially mediate COVID-19 risks in overweight/obesity or low socioeconomic position
Lower plasma angiotensin-converting enzyme 2 (ACE2) levels may partially mediate COVID-19 risks in individuals with overweight/obesity or low socioeconomic position (SEP; referring to low educational attainment), according to a large-scale Mendelian randomization study conducted by researchers at the University of Hong Kong (HKU) and the Chinese University of Hong Kong (CUHK).
Lower plasma ACE2 levels may partially mediate COVID-19 risks in overweight/obesity or low socioeconomic position
10 Jan 2023Capivasertib + fulvestrant boosts PFS in AI-resistant HR+/HER2– advanced breast cancer
The AKT inhibitor capivasertib, when added to fulvestrant, doubled progression-free survival (PFS) in patients with aromatase inhibitor (AI)-resistant hormone receptor-positive (HR+)/HER2*-negative (HER2–) advanced breast cancer (ABC), results of the phase III CAPItello-291 trial showed.